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Abstract
Esophageal cancer develops in the mucosa of the esophagus and spreads toward the 
muscle layer. The nonsurgical treatment for localized, deeply invasive esophageal can-
cer has been external beam radiation therapy (EBRT) and concurrent chemotherapy. 
Recently, intraluminal brachytherapy showed a strong potential for the improvement 
of the therapeutic ratio. It was found that the fractionated high dose rate (HDR) brachy-
therapy offered beneficial palliation for a longer period of time with more durable symp-
tom control. A similar was concluded for advanced unresectable esophageal cancer in 
previously irradiated patients. HDR brachytherapy may be a useful salvage treatment 
option for inoperable patients diagnosed with local esophageal cancer. Although better 
local control can be achieved with higher brachytherapy dose, this increases the risk of 
acute morbidity and late morbidity, especially in the setting of recurrence cancer. It was 
found that the moderate dose of EBRT and HDR brachytherapy could give a better local 
response than EBRT alone.
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1. Introduction
Esophageal cancer is the eighth most common cancer worldwide, besides being the sixth 
most common cause of cancer death. There were 456,000 new cases in the world in 2012 [1]. It 
is four times more common in men than in women; it occurs more frequently among people 
above 45 years of age and reaches its plateau among people at 65–74 years of age. Its mor-
tality is high; it can be as high as 84%. For the locally advanced disease, the 5-year survival 
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is 15–34%. The cornerstone of treatment remains surgery; however, there is evidence that 
survival is favorably influenced when additional therapies, such as chemotherapy or radia-
tion therapy or their combination, or targeted therapies are used for lymph node-positive or 
cT2 or tumors that are larger than cT2. The clinical studies assessing treatment modalities for 
esophageal cancer are diverse: the modalities (chemotherapy, radiation therapy and surgery) 
have been evaluated in various orders and combinations. The number of study subjects has 
rarely been over 100 per study. The study populations have not always been homogeneous; 
different portions of the esophagus were affected, and the study population is sometimes 
mixed, regarding staging and histology.
1.1. Histology
Histology is usually based on the histologic analysis of an endoscopic sample. There are 
two main types of esophageal cancer: squamous cell carcinoma (SCC) and adenocarcinoma. 
Squamous cell carcinoma mostly occurs in the lining in the upper portion of the esophagus. 
Adenocarcinoma develops at the junction between the esophagus and the stomach. Most of the 
tumors are squamous cell carcinoma, but the incidence of adenocarcinoma has been increasing.
1.2. Predisposing factors
Intraepithelial neoplasias, such as epithelial dysplasias and in situ carcinoma, are the most 
significant precursor lesions for the development of esophageal cancer. Generally, it occurs 
a decade prior to carcinoma. The classification of dysplasias is based on the extent of the epi-
thelial involvement. Some of the dysplasias show spontaneous regression. Nearly 30% of the 
severe dysplasias become invasive cancer. Tobacco use and/or consuming alcohol predomi-
nantly increase the risk of esophageal squamous cell carcinoma. Being overweight and/or 
reflux disease can primarily increase the risk of esophageal adenocarcinoma.
The multifocal appearance and intramural spread are common characteristics of esophageal 
cancer. It often spreads through the lymphatic system. Tumors involving the proximal por-
tion of the esophagus may give metastases to the cervical lymph nodes, and tumors involv-
ing the lower portion may also give metastasis to the vicinity of the celiac artery. Cancer can 
infiltrate its surroundings, the pars membranacea of the trachea and the prevertebral fascia.
2. Treatment options
From a surgical point of view, early cancer means that the lesion only involves the mucosa 
and/or submucosa. The treatment option remains surgery for very early cancers (up to stage 
pT1b) while it is palliative in the case of metastatic esophageal cancer. For other cases, addi-
tional therapies, such as chemotherapy and/or radiation therapy may result in improved 
survival.
Regarding epidemiology, tumor biology, pathogenesis, and prognosis, the two main histo-
logical types of esophageal cancer, SCC and adenocarcinoma, are different from each other. 
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The perioperative mortality is higher for squamous cell cancer. It might be due to comorbidi-
ties and the localization of cancer since SCC mostly involves the upper third of the esopha-
gus, and the postoperative mortality is significantly higher for esophageal cancer involving 
the proximal third. Esophageal cancer affecting the upper third and/or middle third of the 
esophagus recurs in a locoregional manner whereas adenocarcinoma can more often metas-
tasize to distant sites. However, the prognosis of adenocarcinoma in an early stage is more 
favorable than that of SCC.
2.1. Chemoradiotherapy
The results of several randomized, phase III studies have been reported so far. Practically, a 
platinum-based medication is used in combination with radiation.
Morbidity and mortality are unclear regarding the use of neoadjuvant chemoradiotherapy. 
Some authors reported an increase in the anastomosis insufficiency and an increase in mortal-
ity, whereas others did not find an increase in mortality. A recent US study analyzed the data 
obtained from 1939 patients who had undergone esophagectomy. Seven hundred and eight 
patients received neoadjuvant therapy. They found no differences in mortality or morbidity [2]. 
The studies are unclear about the stage in which neoadjuvant therapy can be safely omitted. 
The American recommendation [3] states that neoadjuvant therapy is reasonable in the case of 
pT1b (>2 cm in size or dedifferentiated) whereas the European recommendation finds it reason-
able only in stage T3-4 or lymph node-positive disease [4]. Chemoradiotherapy can be used
• Definitively: in inoperable cases or if the disease involves the upper third portion of the 
esophagus, with or without preventive, induction chemotherapy;
• In an adjuvant manner; or
• For a neoadjuvant purpose: if the patient is eligible for surgery (chemoradiotherapy, fol-
lowed by surgery).
In a prospective multicenter study [5] with 186 patients with esophageal squamous cell carci-
noma, three-year survival was significantly higher in patients receiving either pre-operative 
radiation or pre-operative chemotherapy, radiotherapy and surgery. Definitive chemoradio-
therapy can be used in patients who are not surgical candidates or if the disease involves the 
proximal third portion of the esophagus. The main aims of care are to improve the quality of 
life and to maintain the patient’s ability to swallow. The RTOG 8501 [6] study evaluated the 
benefits of concurrent chemotherapy compared to radiation therapy alone. The randomized 
portion of the study included 121 patients, and 61 were enrolled in the chemoradiation arm. 
No one had any distant metastases. Chemotherapy included the combination of continuous 
5-fluorouracil (5-FU) and cisplatin. 1000 mg/m2 of 5-FU was administered daily over 4 days 
during Week 1 and Week 5 of radiation treatment, as well as cisplatin at 75 mg/m2 during the 
first day of Week 1 and Week 5 in combination with 50 Gy irradiation. After completion of 
radiation therapy, another two cycles were administered at unchanged doses. By contrast, 
64 Gy irradiation was delivered as monotherapy in the other arm. Most of the patients (82%) 
had squamous cell carcinoma. The study proved the superiority of chemoradiotherapy over 
radiation therapy alone, regarding both median survival (12.5 vs. 8.9 months) and the 5-year 
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survival (26 vs. 0%). A PRODIGE-5/ACCORD-17 study [7] included 267 patients with up to 
IV/A stage esophageal cancer. Cisplatin and 5-FU used in the RTOG 8501 study were com-
pared with the administration of six cycles of FOLFOX. FOLFOX + radiation yielded results 
similar to those of the regimen used in the RTOG study (median PFS: 9.7 vs. 9.4 months), but 
it was significantly less toxic.
Primarily, the combination of taxane and platinum was assessed in the neoadjuvant setup. 
The most commonly used paclitaxel (50 mg/m2) and carboplatin (AUC2, weekly over 5 weeks) 
were at least as efficient as the combination of platinum and 5-FU [8]; therefore, it is accepted 
as definitive treatment. In general, definitive chemoradiation is a choice of treatment for those 
patients who are not suitable for surgery or who do not consent to surgery.
Since distant metastases are present nearly in 75% of patients with locally advanced esophageal 
cancer, induction chemotherapy prior to chemoradiotherapy would be a rational choice. Usually, 
patients with locally advanced but resectable esophageal cancer were enrolled in the studies. 
Since there are no phase III study results, these regimens have not become recommendations. 
Seventy-two patients participated in the phase II, RTOG 0113 study [9]. The induction treatment 
included 5-FU (5 × 700 mg/m2), cisplatin (5 × 15 mg/m2) and paclitaxel (200 mg/m2) or cisplatin 
(75 mg/m2) and paclitaxel (175 mg/m2), which was followed by a similar combination (5-FU + 
paclitaxel or cisplatin + paclitaxel) administered simultaneously with a total radiation dose of 50.4 
Gy. Median survival showed no significant differences, and the toxicity was similar in both arms.
Neoadjuvant chemoradiotherapy can be used in those patients who are suitable for surgery. 
The method of treatment is practically identical to that of the definitive chemoradiotherapy. 
The aim of the treatment of inoperable patients is palliative, and the aim is to improve the 
proportion of operability or recovery. The studies frequently yielded contradictory results. 
However, based on several clinical trials and meta-analyses, neoadjuvant chemoradiotherapy 
proved to be superior to surgery alone in patients with locally advanced esophageal cancer. 
A significant survival benefit was found in the CROSS study [10] in which 366 patients with 
potentially resectable esophageal or gastroesophageal junction cancer were randomized to 
get either preoperative chemoradiotherapy (50 mg/m2 paclitaxel a week + carboplatin AUC2, 
concurrent radiotherapy with a total dose of 41.4 Gy over 5 weeks) or surgery alone. Patients 
tolerated the combined treatment well. There were no significant differences in mortality or 
morbidity. The complete resection rate was 92 vs. 69% in favor of the combined treatment, 
and the complete pathological remission (pCR) ratio was 29% in patients receiving chemo-
radiotherapy. There was a significant difference in median overall survival (preoperative 
chemoradiotherapy followed by surgery vs. surgery alone: 49.4 vs. 24.0 months).
In the FFCD 9901 study [11], the efficacy of preoperative chemoradiotherapy was evaluated 
in patients with small-sized, resectable tumors. 195 patients with stage I or II disease were 
randomized into the preoperative chemoradiation arm (two cycles of 5-FU at 800 m/m2 daily 
at Days 1–4 and 29–32, plus cisplatin at 75 mg/m2 at Day 1 or Day 2 of the cycle, in both cycles, 
plus a total dose of 45 Gy concurrent radiation) or the surgery alone arm. During this study 
with a median follow-up of 93.6 months, there were no significant differences in the 3-year 
survival. No significant survival benefits were noted in any of the subgroups. Based on these 
data, the combined treatment may not result in any survival benefit.
Esophageal Abnormalities60
Numerous meta-analyses have dealt with the comparison of the effects on survival regarding 
the trimodal treatment or surgery alone. One of the latest studies was published by Sjoquist 
and his colleagues [12]. It includes the twelve most significant neoadjuvant chemoradia-
tion studies. The reducing effect of neoadjuvant chemoradiotherapy on mortality proved 
to be significant, which led to an absolute survival benefit of 8.7% after two years. It was 
independent of the histologic type of the tumor, and it was not associated with increased 
perioperative mortality, either.
In addition to the conventional cisplatin + 5-FU therapy, adding paclitaxel to platinum has 
become more popular lately. Results of ten studies were analyzed in another meta-analysis, 
and a comparison was made between the efficacy of paclitaxel together with platinum and 
the efficacy of platinum together with 5-FU. The analysis proved the benefit provided by neo-
adjuvant chemoradiation therapy over both combinations. The risk of mortality was signifi-
cantly reduced with both chemotherapy combinations, but the benefit was more pronounced 
in the taxane arm. However, it was only statistically significant in the case of squamous cell 
cancer [8]. Some small-sized studies have found the combination of docetaxel and platinum 
effective [13, 14].
Based on the consequent results of several clinical studies, the response to perioperative treat-
ment, especially the pCR, is an important indicator of better overall survival. Thus, intensi-
fication of the perioperative treatment could be a potential approach. Based on the results 
of 22 studies, survival of those patients who achieved pCR as a result of treatment was 2–3 
times longer compared to those patients who had residual cancer in the resection specimen 
obtained via surgery following neoadjuvant chemoradiotherapy. During the intensification 
of neoadjuvant treatments, the employments of chemotherapy prior to chemoradiation, as 
well as the increase of the number of the agents have been studied. According to the INT0123 
study, radiation dose intensification resulted in no improvement in either the survival or the 
local control [15].
Some work was conducted in relation to the non-surgical treatment options of patients with 
squamous cell carcinoma of the esophagus. Trimodal therapy (chemoradiotherapy followed 
by surgery) was compared with chemoradiotherapy by Stahl et al. and in the FFCD 9102 
study. Stahl et al. [16] enrolled 172 patients. Patients received three cycles of bolus 5-FU, leu-
covorin, etoposide, cisplatin (FLEP) followed by chemoradiotherapy including a total dose 
of 40 Gy irradiation and cisplatin and etoposide chemotherapy. Patients then underwent 
either observation or surgery. In the surgery arm, 62 out of 86 patients underwent surgery. 
However, there were no significant differences in overall survival. The two-year progression-
free survival was more beneficial for those patients who had undergone surgery (64.3 vs. 
40.7%). Notably, both the radiation dose and the intensity of chemotherapy were lower than 
those used in conventional treatments. In the FFCD 9102 study [17], 259 patients with locally 
advanced, resectable SCC were randomized into two arms following low-dose chemora-
diotherapy. If a therapeutic response was noted after the induction treatment, surgery was 
performed or chemoradiotherapy was completed. No significant differences were found in 
overall survival between the two treatment groups. However, the 3-month mortality was sig-
nificantly higher (p = 0.002) in the surgery arm (9.3 vs. 0.8%).
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Little is known about the results of the nonsurgical treatment of patients with adenocarci-
noma. Based on a retrospective analysis of the results of 276 patients treated with definitive 
chemoradiotherapy for esophageal adenocarcinoma at the university of texas MD Anderson 
cancer center [18]. After a median follow-up of 54.3 months, 33.3% of the patients never had 
a relapse. Local relapse was present in 51% of the patients, and distant dissemination was 
detected in 43.5% of the patients.
There are not enough phase III results in relation to adjuvant chemoradiation. In a retrospec-
tive study by Bedard et al. [19], data of 38 patients who had undergone surgery for node-
positive esophageal cancer, had received postoperative adjuvant chemoradiation (concurrent 
or sequential radiation therapy plus cisplatin and 5-FU ± epirubicin) were compared with 
data of patients who had undergone surgery only. Both the local control and median survival 
proved to be better in patients receiving adjuvant treatment, and so did overall survival. In 
another retrospective analysis [20], benefits of adjuvant chemoradiation were evaluated in 
304 patients who had undergone surgery for node-positive esophageal squamous cell cancer. 
Based on the data, both the 5-year overall survival and the disease control proved significantly 
better in patients who had also received chemotherapy in addition to radiotherapy. According 
to a prospective study [21] that evaluated chemoradiation vs. chemotherapy and included 45 
patients, neither survival benefit nor improved locoregional control was shown in the chemo-
radiation treatment arm relative to chemotherapy alone (cisplatin + 5-FU over 5 weeks plus 50 
Gy of irradiation over 5 weeks vs. cisplatin + 5-FU over 5 weeks).
2.1.1. Neoadjuvant chemotherapy
Eight hundred and two patients with either SCC or adenocarcinoma were randomized in the 
MRC OEO2 study [22]. Patients received either two cycles of cisplatin + 5-FU preoperatively or 
underwent surgery primarily. The 5-year overall survival was 23 vs. 17% in favor of the neo-
adjuvant treatment regimen. In Sjoquist’s meta-analysis, data of 1981 patients were assessed. 
Nine neoadjuvant chemotherapies were compared to surgery alone [12]. Chemotherapy 
reduced mortality in the entire patient population receiving neoadjuvant chemotherapy. It 
was significant in patients with adenocarcinoma. Based on these, neoadjuvant chemotherapy 
seems to be superior to surgery alone.
It is unclear whether neoadjuvant chemotherapy can be an alternative to neoadjuvant chemo-
radiation therapy. Stahl et al. [23] enrolled 119 patients with adenocarcinoma involving the 
lower third portion of the esophagus or the gastroesophageal junction. In one of the arms, 
patients received 15 weeks of chemotherapy (cisplatin + leucovorin + continuous 5-FU) fol-
lowed by surgery. In the other arm, 12 weeks of chemotherapy were followed by concurrent 
chemoradiation therapy (low-dose radiation therapy and concurrent cisplatin + etoposide) 
over 3 weeks, and surgery was then performed. The ratio of pCR was significantly higher 
in the arm that included chemoradiation therapy (2 vs. 15.6%). However, there were no sig-
nificant differences in median survival and the 3-year overall survival between the two treat-
ment arms. Burmeister et al. [24] received similar results when they evaluated 75 patients with 
adenocarcinoma. Regarding pCR and R1 resection, chemoradiotherapy was significantly more 
beneficial, but there were no significant differences in median survival.
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Briefly, chemotherapy can be employed as part of chemoradiation, in a neoadjuvant manner, 
in an adjuvant manner, or as palliation in metastatic disease.
3. Brachytherapy of esophageal cancer
The results in a large cohort of patients indicated that HDR brachytherapy alone was an 
effective method for the palliation of advanced esophageal cancer [25]. Similar long-term 
results were reported in favor of treatments involving concurrent chemoradiotherapy fol-
lowed by HDR brachytherapy [26]. Although brachytherapy was found to be preferable, 
there are studies (such as Refs. [27, 28]) suggesting the stent placement may play an impor-
tant role for the palliation of disease. In that case, the prognostic models were used as evi-
dence-based tools in decision making. However, the health-related life quality was reported 
to be improved in patients treated with the HDR brachytherapy. Recent studies suggested 
the usage of Californium-252 neutron brachytherapy combined with EBRT for esophageal 
cancer. The treatment resulted in favorable local control and long-term survival rates with 
tolerable side effects [29]. Patient selection, timing of brachytherapy and dose specifications 
were well documented [30–32]. Clinicians continue to urge caution in using brachytherapy 
treatment techniques since severe toxicity can occur post treatment [15, 26, 30]. Therefore, the 
addition of brachytherapy, with consequently high surface doses, should be limited to well-
selected patients [33].
For that reason, the clinical implementation and accuracy in dose delivery is crucial for 
favorable treatment outcomes. The radiation dose is delivered using esophageal transoral 
or transnasal applicators with an external diameter of 0.6–1 cm. Ideally, the single channel 
applicator needs to be placed centrally in the lumen of the esophagus; however, there exists 
a possibility that the applicator will be closer to one side of the lumen, delivering a larger 
dose to the epithelium, lamina propria and muscularis mucosa, resulting in local esophageal 
complications. In those cases, stricture formation, fistula and esophageal ulceration are the 
common late toxicities of HDR brachytherapy [34]. A possible difference in the delivered 
dose is caused by disagreements in the choice of the dose point (i.e. mucosal surface or cer-
tain distance from the central line of the applicator) in various institutions, as reported in 
Ref. [35]. For instance, it was reported in the long-term experience with esophageal brachy-
therapy treatment [36] that radiation was delivered at a level of 5 mm below the surface of 
the mucosa. However, no correlation was found between the post-treatment complications 
and the diameter of the brachytherapy applicator [37]. In most of the HDR brachytherapy 
treatments, 3D treatment plans were generated using computed tomography (CT) images; 
however, magnetic resonance imaging (MRI) can be used to assist the localization of the 
tumor and the applicator [38]. The treatment planning for the esophageal cancer patient is 
performed using the TG-43 formalism [39], since the dose calculation accuracy of the TPS 
was confirmed in a homogeneous medium [40].
Overall, this HDR treatment is demonstrated to be well-tolerated and effective for superficial 
primary and recurrent esophageal cancer in inoperable patients [41, 42]. The authors concluded 
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that dose escalation with larger diameter applicators may allow for improved therapeutic cov-
erage without exceeding the organs ate risk tolerances [43]. The latest research in the combined 
approach (EBRT and HDR) to palliation in esophageal cancer together with the review of the 
current techniques is reported in Refs. [44, 45].
3.1. Clinical implementation
To decrease the dose to the organs at risk in the upper gastrointestinal region a novel disposable 
brachytherapy transoral balloon centering esophageal applicator (BCEA) with five indepen-
dently inflatable balloons was developed [44]. The complete treatment process for this appli-
cator consisted of three principal steps: pre-treatment preparation, treatment planning and 
treatment delivery (Figure 1). This applicator allows for the central placement of the radioactive 
source during treatment. The BCEA allows for the treatments outside the balloon region with 
the constraint where the BCEA becomes similar to the standard esophageal applicator (EA). 
Figure 1. The detailed process map of the treatment was developed for improved treatment plan generation and quality 
assurance of the process.
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The experience in the treatment of esophageal cancer using a standard intraluminal esophageal 
applicator (EA) was summarized in Ref. [45]. Unlike with the transnasal insertion (EA) where 
the endoscope would be placed via the anesthetized nose past turbinates and nasopharynx 
behind the larynx and into the esophagus, the BCEA is placed transorally.
3.2. Treatment planning and delivery
The BCEA positions the catheter centrally when the balloons are inflated. Due to that fact, the 
treatment plan can be additionally optimized (not the case for the standard EA) for improved 
dose distribution and conformality. The treatment length was defined as a pretreatment 
tumor length with 1–2 cm distal and proximal margin determined by pretreatment imaging 
and confirmed by the CT images.
The prescription dose is usually planned to be delivered to the diameter of 1 cm with respect to 
the central catheter with an additional optimization to avoid the critical anatomical structures 
such as the heart, lung, pharyngeal constrictor and spine. The dose calculation is performed 
using the TG-43 formalism that includes the anisotropy corrections. With the standard EA, 
the dose point is defined at the mucosal surface or a certain distance from the central line of 
the applicator with identical dwell times along the treatment length. This was mostly done 
to minimize the uncertainties in dose delivery related to the positioning of the EA inside the 
esophagus. In standard approach when EA is used the dose optimization outside the balloon 
region should be avoided due to the complicated position reproducibility. Figure 2 shows the 
differences in the treatment plans between the EA and BCEA.
The centrally placed catheter inside the esophagus lumen resulted in enhanced dose distribu-
tion and reproducibility in multi fractional treatment (Figure 2). The position of the applicator 
and the balloon diameters can be verified before the treatments using the planning CT images 
and the CT images obtained prior to each fraction. Three methods can be used to verify the 
Figure 2. Sagittal images show: (a) the non-optimized plan using the EA and (b) optimized dose distribution achieved 
with the BCEA.
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proper positioning of the BCEA prior to each treatment: (a) using an external marker to verify 
the length of the catheter in the patient, (b) evaluation of the position of 12 radio-opaque mark-
ers on the exterior side of the catheter in the CT images, and (c) measurements of the diameters 
of the balloons on CT images after inflation to confirm that they were properly inflated.
4. Conclusion
In this chapter, various aspects of esophageal cancers were disused such as histology, predis-
posing factors and treatment options. It was found that the moderate dose of EBRT and HDR 
brachytherapy could give a better local response than EBRT alone. Therefore, the brachy-
therapy of esophageal cancer was elaborated in more detail.
Classically, one of the limitations for the deployment of esophageal brachytherapy has been 
the difficulties associated with the placement and tolerance of the transnasal applicator [44]. 
The common adverse effects included significant pain on placement and for the duration of 
its indwelling. Nasal bleeding, often significant, can be seen from both the scope and catheter 
placement. There is often the need of significant pain medicine to tolerate this procedure. 
These effects are pronounced if the applicator is kept in place for an extended period of time.
Long-term toxicities and the correlation between the formation of a fistula or ulceration and 
the novel design of the BCEA are the topics that can be additionally investigated using the 
data of more patients treated with the novel BCEA and longer follow-up. Due to the limited 
number of patients, it is not yet possible to conclude if the patients benefit from the treatment 
using the centrally placed applicator. Furthermore, due to the provision to additionally opti-
mize the dose, there exists a possibility of dose escalations for certain patients, depending on 
their anatomy and the spread of disease. The initial implementation of this applicator required 
strict and careful testing, especially in the determination of the accurate treatment length that 
would allow the radioactive source to be sent to the most distal position (first dwell position). 
Multiple tests and an interobserver agreement are required since the inaccurate results of this 
test can potentially offset the whole treatment, causing adverse events. Therefore, the treat-
ment length and BCEA applicator positioning should be evaluated before each fraction.
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